Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany

Journal of Medical Economics

Volumn 18, Issue 2, 2015, Pages 155-165

  Walter, Evelyn ^a   Odin, Per ^b  

^a IPF Institute for Phamaeconomic Research   (Austria)

^b Klinikum Bremerhaven Reinkenheide   (Germany)

Author keywords

Advanced Parkinson disease; Apomorphine; Cost utility analysis; Germany; UK

Indexed keywords

APOMORPHINE; CARBIDOPA PLUS LEVODOPA; ANTIPARKINSON AGENT; CARBIDOPA; GEL; LEVODOPA;

ARTICLE; BRAIN DEPTH STIMULATION; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; GERMANY; HEALTH CARE QUALITY; OUTCOME ASSESSMENT; PARKINSON DISEASE; QUALITY ADJUSTED LIFE YEAR; UNITED KINGDOM; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; GEL; HUMAN; PROBABILITY; QUALITY OF LIFE; STATISTICAL MODEL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIPARKINSON AGENTS; APOMORPHINE; CARBIDOPA; COST-BENEFIT ANALYSIS; DEEP BRAIN STIMULATION; DRUG ADMINISTRATION SCHEDULE; GELS; GERMANY; HUMANS; INJECTIONS, SUBCUTANEOUS; LEVODOPA; MARKOV CHAINS; MODELS, ECONOMETRIC; PARKINSON DISEASE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS;

EID: 84923211483     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.979937     Document Type: Article

References (47)

1. de Lau LML, Breteler Monique MB. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-35
2. von Campenhausen L, Bornschein B, Wick R, et al. Revalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005;15: 473-90
3. Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986;36:1528-30
4. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease A community-based study. Oxf J Med Brain 2000;123:2297-305
5. Hilker R, Antonini A, Odin P. What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? J Neural Transm 2011;118:907-14
6. Deuschl G, Schade-Brittinger C, Krack P. A randomized trial of deep-brain stimulation for Parkinson's Disease. N Engl J Med 2006;355:896-908
7. Eggington S, Valldeoriola F, Chaudhuri KR, et al. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease. J Neurol 2014;261:106-16
8. Dams J, Siebert U, Bornschein B, et al. Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease. Mov Disord 2013;28:763-71
9. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology 2001;57:663
10. Lowin J, Bergman A, Chaudhuri KR, et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK. J Med Econ 2011;14:584-93
11. Valldeoriola F. Cost and efficacy of therapies for advanced Parkinson's disease. Barcelona, Spain: Institut de Neurociè ncies, Hospital Clínic, Universitat de Barcelona, 2011
12. Willis M, Persson U, Zoellner Y, et al. Reducing uncertainty in value-based pricing using evidence development agreements. The case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa) in Sweden. Appl Health Econ Health Policy 2010;8:1-10
13. Findley LJ, Lees A, Apajasalo M, et al. Cost-effectiveness of levodopa/carbi-dopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. Curr Med Res Opin 2005;21:1005-14
14. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisals. 2008. NICE, UK. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed April 13, 2012
15. IQWIG. Kosten und Nutzen in der Medizin Die Analyse von 'Effizienzgrenzen': Allgemeine Methoden zur Bewertung von Verhältnissen zwischen Nutzen und Kosten; Cologne, 2009
16. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decsn Mak 1993;13:322-38
17. Keeler E. Decision trees and Markov models in cost-effectiveness research. In: Sloan FA, ed. Valuing Health Care. Cambridge: Cambridge University Press, 1996. p. 185-205
18. García Ruiz PJ, Ignacio AS, Pensado BA, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 2008;23:1130-6
19. Pollak P, Champay AS, Gaio JM, et al. Subcutaneous administration of apo-morphine in motor fluctuations in Parkinson's disease. Rev Neurol (Paris) 1990;146:116-22
20. Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov Disord 1995;10:37-43
21. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apo-morphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-7
22. Chaudhuri KR, Critchley P, Abbott RJ, et al. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet 1988;2:1260
23. Stocchi F, Bramante L, Monge A, et al. Apomorphine and lisuride infusion. A comparative long-term study. Adv Neurol 1993;60:653-5
24. De Gaspari D, Siri C, Landi A, et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subtha-lamic nucleus. J Neurol Neurosurg Psychiatry 2006;77:450-3
25. Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151-66
26. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-9
27. Raudino F, Garavaglia P, Pianezzola C, et al. Long-term experience with continuous duodental levodopa-carbidopa infution (Duodopa): report of six patients. Neurol Sci 2009;30:85-6
28. Lisitchkina H, Ide J, Zutter D. Therapieerfahrung mit der pumpengesteuerten en-teralen Infusion eines Levodopa/Carbidopa-Gels bei fortgeschrittenem Morbus Parkinson. Schweizer Archiv für Neurologie und Psychiatrie 2011;162:122-6
29. Palmer CS, Schmier JK, Snyder E, et al. Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease. Qual Life Res 2000;9:819-27
30. Davey P, Rajan N, Lees M, et al. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model. Value Health 2001;4:308-15
31. Palmer CS, Nuijten MJ, Schmier JK, et al. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States. Pharmacoeconomics 2002;20:617-28
32. Ceballos-Baumann A. Continuous subcutaneous infusion therapy with the Apomorphine Pump. Akt Neurol 2011;38:17-26
33. Dams J, Bornschein B, Reese JP, et al. Modelling the cost effectiveness of treatments for Parkinson's disease: A Methodological Review. Pharmacoeconomics 2011;29:1025-49
34. Findley LJ, Wood E, Lowin J, et al. The economic burden of advanced Parkinson's disease: an analysis of a UK patient dataset. J Med Econ 2011;14:130-9
35. Pereira E, Nandi D, Aziz T. Deep brain stimulation: an underused panacea? ACNR 2008;8:4
36. Gold M, Siegel J, Russel L, et al, eds. Cost-effectiveness in health and medicine. Philadelphi, PA: WB Staunders, 1996
37. Kristiansen IS, Bingefors C, Nyholm D, et al. The cost-effectiveness of continuous duodenal delivery of levodopa (Duodopa) in patients with severe Parkinsons disease [abstract]. Mov Disord 2005;20(10 Suppl):80
38. Lundqvist C. Continuous levodopa for advanced Parkinson's disease. Neuropsychiatr Dis Treat 2007;3:335-48
39. Dodel R, Eggert KM, Singer MS, et al. Costs of drug treatment in Parkinsons disease. Mov Disord 1998;13:249-54
40. Meissner W, Trottenberg T, Klaffke S, et al. Apomorphinterapie versus tiefe Hirnstimulation. Nervenarzt 2001;72:924-7
41. Zhao YJ, Wee HL, Chan YH, et al. Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord 2010;25:710-6
42. Reddy P, Martinez-Martin P, Todorova A, et al. The EuroInf Study: a multi-centre European comparative study of apomorphine versus intrajejunal levodopa infusion in a real life cohort of Parkinson's patients [abstract]. Mov Disord 2013;28(1 Suppl):596
43. The World Standard Drug Database. online database from SafeScript Limited, London. http://admin.safescript.com/. Accessed April 2, 2014
44. LAUER Taxe [LAUER FISCHER GmbH web site]. online database from Lauer Fischer Germany. www2.lauer-fischer.de. Accessed April 12, 2014
45. Personal Social Services Research Unit [The University of Kent]. Unit costs of health and social care 2011. Personal Social Services Research Unit PSSRU, Kent. http://www.pssru.ac.uk/pdf/uc/uc2011/uc2011.pdf. Accessed October 4, 2012
46. EBM-einheitlicher Bewertungsmabstab. Kassenaerztliche Bundesvereinigung. 2014. Kassenä rtzliche Bubdesvereinigung, Berlin. http://www.kbv.de. Accessed April 16, 2014
47. Farkouh RA, Wilson MR, Tarrants ML, et al. Cost-effectiveness of Rasagiline compared with first-line early Parkinson disease therapies. Am J Pharm Benefits 2012;3:99-107